StreetAlpha.app
Home › Stocks › INSM

INSMED Inc (INSM)

Healthcare
$121.86
▼ −0.83%
LAST CLOSE · NOV 17

INSMED develops and sells medicines for serious lung diseases and other conditions, based in Bridgewater, New Jersey. It last closed at $121.86 on Nov 17, down 0.83% on the day. The average 12-month price target from 6 analysts is $204.50 (+67.8% from the last close), with a high of $220.00 and a low of $188.00. Analyst consensus is Strong Buy, based on the latest ratings from 6 firms (6 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 3 whale options trades in INSM, 100% of them bullish and 0% bearish. In the past 30 days there were 12 dark pool prints totaling $10.1M, the largest $1.6M.

AI Auto Pilots
Is INSM in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$1.5B
+240.0% vs a year ago
Net income
−$605.6M
−39.9% margin
EPS (diluted)
−$2.81
Free cash flow
−$627.6M
−41.3% margin
Valuation
Market cap
$26.7B
219.4M shares
P/E
–
No P/E while losing money
Price to sales
17.6
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$396.6M
At Sep 30
Debt
$546.8M
At Sep 30
Shareholder equity
$726.2M
Shares outstanding
219.4M
At Oct 23
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $188.5M$188.5MFY2021FY2022: $245.4M$245.4MFY2022FY2023: $305.2M$305.2MFY2023FY2024: $363.7M$363.7MFY2024FY2025: $606.4M$606.4MFY2025

From INSM's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Oct 29). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 6 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
6firms
6 Buy0 Hold0 Sell
Each firm's latest rating on INSM in the past 90 days
Average 12-month target
$204.50
▲ 67.8% upside

Based on 6 analysts who set a price target on INSM in the past 90 days. The average target is $204.50, with a high of $220.00 and a low of $188.00, compared with the last close of $121.86.

$82$131$181$230PAST 19 TRADING DAYS12-MONTH TARGETSHIGH $220AVG $204.50LOW $188Jun 1LAST CLOSE+12 MO$82$131$181$230PAST 19 DAYSTARGETSHIGH $220AVG $204.50LOW $188Jun 1LAST CLOSE+12 MO
Highest target$220.00
Average target$204.50
Lowest target$188.00
Latest rating changes
HC Wainwright & Co.Assumed coverage
Nov 4Buy$220
GuggenheimTarget lowered
Nov 2Buy$205 → $201
Morgan StanleyTarget raised
Oct 21Buy$212 → $213
HC Wainwright & Co.Reiterated
Oct 12Buy$220
BarclaysMaintained
Sep 30Buy$207
DateFirmActionRatingPrice target
Nov 4HC Wainwright & Co.Assumed coverageBuy$220
Nov 2GuggenheimTarget loweredBuy$205 → $201
Oct 21Morgan StanleyTarget raisedBuy$212 → $213
Oct 12HC Wainwright & Co.ReiteratedBuy$220
Sep 30BarclaysMaintainedBuy$207
Loading…

Technical Analysis

INSM · as of the Nov 17 close · updated after every close
Bounce inside a longer downtrend, nearing overbought

The stock is 11% above its 20 day and 9% above its 50 day average. It is sitting right on its 200 day average, a level many traders watch. Momentum is strong (RSI 65), near overbought. The nearest support is the Pivot at $121.23, and the nearest resistance the 200 day average at $122.83.

Short trendBullish
Long trendBearish
MomentumStrong
StretchNear overbought
VolatilityHigh, 3.9%/day
Key levels
$212.7552 week high+74.6%
$123.93Pivot R1+1.7%
$122.90Swing high (Sep 25)+0.9%
$122.83200 day average+0.8%
$121.86Last close
$121.23Pivot−0.5%
$121.04Swing low (Sep 9)−0.7%
$119.17Pivot S1−2.2%
$113.41100 day average−6.9%
$110.6950 day average−9.2%
$108.9620 day average−10.6%
$90.3952 week low−25.8%
Indicators
RSI (14)64.73Strong, overbought above 70Neutral
MACD4.39Above its signal lineBullish
Stochastic92.8Near the top of its rangeOverbought
ADX (14)31.1Trending up
Williams %R-13.8Oversold below −80, overbought above −20Overbought
CCI (20)97.5Oversold below −100, overbought above 100Neutral
Rate of change+16.7%Change over 10 sessionsBullish
ATR (14)$4.80Typical daily range, 3.9% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Below
What happened before, for INSM

What happened before

See how INSM did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Whale flow leans bullish3 bullish and 0 bearish whale options trades in the last 90 days. See Whale Flow
November seasonalityHow INSM usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How INSM has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
3
Bullish
3
100%
Bearish
0
0%
Date span
Oct 6 – Oct 27
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
12
Notional
$10.1M
Largest print
$1.6M
Loading…

INSM Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲396 buying vs 310 selling
  • ▼Held by funds -2.4 pts
  • ▲Funds holding +33
  • ▼Superinvestors: 1 added, 5 cut
  • ▼Put/call 0.29 to 0.37
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding704671+4.9%
In funds' top 101716+6.3%
Held by funds99.9%102.3%−2.4 pts
New / increased126 / 270114 / 248+9.4%
Reduced / sold out222 / 88230 / 122−11.9%
Put/call ratio0.370.29+25.1%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See INSM institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether INSM is in one of them and how their past INSM trades turned out.

INSM in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered INSM in an article yet. Here's the latest on the wider market.

INSM Congress Trades

All congress trades →
Trades, 12 months
3
Buys
1
33%
Sells
2
67%
People
3
Last filed Sep 22
Who traded INSM · since 2022
Latest 5 filings of 11
$15K – $50KTraded Jul 17, 2026Filed Sep 22, 2026
Josh GottheimerSell (partial)
$1K – $15KTraded Jun 10, 2026Filed Jul 7, 2026
$1K – $15KTraded Oct 3, 2025Filed Nov 18, 2025
Gilbert CisnerosSell (partial)
$1K – $15KTraded Sep 22, 2025Filed Oct 10, 2025
Gilbert CisnerosSell (partial)
$1K – $15KTraded Aug 8, 2025Filed Sep 12, 2025
PersonTypeAmountTradedFiledDelay
Donald J TrumpExecutive branchBuy$15K – $50KJul 17, 2026Sep 22, 202667 d
Josh GottheimerD · NJSell (partial)$1K – $15KJun 10, 2026Jul 7, 202627 d
Gilbert CisnerosD · CASell$1K – $15KOct 3, 2025Nov 18, 202546 d
Gilbert CisnerosD · CASell (partial)$1K – $15KSep 22, 2025Oct 10, 202518 d
Gilbert CisnerosD · CASell (partial)$1K – $15KAug 8, 2025Sep 12, 202535 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About INSMED

INSMED is a biopharmaceutical company based in Bridgewater, New Jersey. It develops and sells medicines for serious diseases, with a focus on lung conditions. Its two marketed products are ARIKAYCE, an inhaled treatment for lung disease caused by MAC, and BRINSUPRI, an oral tablet for bronchiectasis, a chronic lung disease. Its other programs target pulmonary hypertension, an immune condition called hidradenitis suppurativa, and neurological diseases such as Duchenne muscular dystrophy and ALS. Its patients are people living with these conditions.

Headquarters
Bridgewater, NJ